WASHINGTON-Facing Congressional criticism that it isn't doing enough to prevent counterfeit-drug imports, the Food and Drug Administration (FDA) is reviewing thousands of drug shipments from foreign countries. The FDA will be examining the drugs to see if counterfeit ingredients have made their way into US drug-making plants. Congressional concerns stem from the potential of substandard ingredients, manufactured in foreign drug plants, being used by the nation's drug makers. The FDA, while often not inspecting these drugs, says it has no evidence of a substantial problem, nor does it believe that the public is at any risk of harm from such substances. Also part of the investigation is increased enforcement and warnings to importers to help regulators keep track of shipments. For more information, visit www.fda.gov.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.